Details

Autor(en) / Beteiligte

• DELMAN, Keith A
• BENNETT, Joseph J
• YUMAN FONG
• ZAGER, Jonathan S
• BURT, Bryan M
• MCAULIFFE, Priscilla F
• PETROWSKY, Henrik
• KOOBY, David A
• HAWKINS, William G
• HORSBURGH, Brian C
• JOHNSON, Paul

Titel

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

Ist Teil von

• Human gene therapy, 2000-12, Vol.11 (18), p.2465-2472

Ort / Verlag

Larchmont, NY: Liebert

Erscheinungsjahr

2000

Quelle

MEDLINE

Beschreibungen/Notizen

• Herpes simplex viruses (HSV) type 1 are the basis of a number of anticancer strategies that have proven efficacious in animal models. They are natural human pathogens and the majority of adults have anti-HSV immunity. The current study examined the effect of preexisting immunity on the response to herpes-based oncolytic viral treatment of hepatic metastatic cancer in a murine model designed to simulate a clinical approach likely to be utilized for nonneurological tumors. Specifically, the anticancer effects of NV1020 or G207, two multimutated HSV-1 oncolytic viruses, were tested in immunocompetent mice previously immunized with a wild-type herpes simplex type 1 virus. Mice were documented to have humoral as well as cell-mediated immunity to HSV-1. Tumor response to oncolytic therapy was not measurably abrogated by immunity to HSV at the doses tested. The influence of route of viral administration was also tested in models of regional hepatic arterial and intravenous therapy. Route of viral administration influenced efficacy, as virus delivered intravenously produced some detectable attenuation while hepatic arterial therapy remained unaffected. These results demonstrate that when given at appropriate doses and in reasonable proximity to tumor targets, HSV-based oncolytic therapy can still be expected to be effective treatment for patients with hepatic malignancies.